Journal of Biological SystemsSystems BiologyPeer-reviewed journal article
Studying the age of onset and detection of Chronic Myeloid Leukemia using a three-stage stochastic model
Suryadeepto NagiD, Ananda Shikhara BhatiD, Siddhartha Pratim ChakrabartyiD
Abstract
Chronic Myeloid Leukemia (CML) is a biphasic malignant clonal disorder that progresses, first with a chronic phase, where the cells have enhanced proliferation only, and then to a blast phase, where the cells have the ability of self-renewal. It is well-recognized that the Philadelphia chromosome (which contains the BCR-ABL fusion gene) is the "hallmark of CML". However, empirical studies have shown that the mere presence of BCR-ABL may not be a sufficient condition for the development of CML, and further modifications related to tumor suppressors may be necessary. Accordingly, we develop a three-mutation stochastic model of CML progression, with the three stages corresponding to the non-malignant cells with BCR-ABL presence, the malignant cells in the chronic phase and the malignant cells in the blast phase. We demonstrate that the model predictions agree with age incidence data from the United States. Finally, we develop a framework for the retrospective estimation of the time of onset of malignancy, from the time of detection of the cancer.
- Citations
- 0
- FWCI
- 0.00
- Field percentile
- 3th percentile
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Statistical inference of the cellular origin of chronic myeloid leukemia using a discrete-parameter ABC-PMC framework
Sylvie Vande Velde, Céline Engelbeen, … Sophie Hautphenne·bioRxiv·Oct 17, 2025
- State-transition Modeling of Blood Transcriptome Predicts Disease Evolution and Treatment Response in Chronic Myeloid Leukemia
D. E. Frankhouser, R. C. Rockne, … G. Marcucci·bioRxiv·Oct 11, 2023
- Cell state transitions drive the evolution of disease progression in B-lymphoblastic leukemia
Curtis A. Gravenmier, Sadegh Marzban, … Jeffrey West·Cancer Research CommunicationsPeer-reviewed·Nov 26, 2025
- A retrospective case-control study for Clinical Validation of mutated ZNF208 as a novel biomarker of fatal blast crisis in Chronic Myeloid Leukemia
Nawaf Alanazi, Abdulaziz Siyal, … Zafar Iqbal·medRxiv·Mar 9, 2024
- Clinicopathologic Correlates and Natural History of Atypical Chronic Myeloid Leukemia
G. Montalban-Bravo, R. Kanagal-Shamanna, … G. Garcia-Manero·bioRxiv·Sep 10, 2020
- Utilization of targeted resequencing for clinical validation of mutated FANCD2 gene as a promising molecular biomarker of early disease progression in Chronic Myeloid Leukemia
Nawaf Alanazi, Abdulaziz Siyal, … Zafar Iqbal·medRxiv·Dec 19, 2023